CBD and CBG May Reverse Fatty Liver Disease, Study Finds

A Breakthrough for the World's Most Common Liver Condition

Fatty liver disease affects roughly a quarter of the global population, and until now, treatment options have been frustratingly limited. A groundbreaking study from the Hebrew University of Jerusalem has identified two non-psychoactive cannabis compounds — cannabidiol (CBD) and cannabigerol (CBG) — as potential game-changers in the fight against this pervasive condition.

Published in the British Journal of Pharmacology, the research demonstrates that both CBD and CBG can improve liver health through two distinct biological mechanisms: boosting cellular energy reserves and restoring the organ's internal cleanup systems. If these findings translate to human treatments, they could represent the first targeted therapy for a disease that currently has no FDA-approved drug treatment.

Understanding Fatty Liver Disease

Metabolic dysfunction-associated steatotic liver disease, commonly known as fatty liver disease, occurs when excess fat accumulates in liver cells. The condition exists on a spectrum, ranging from simple fat accumulation to inflammation, scarring, and eventually cirrhosis or liver failure.

The disease is closely linked to obesity, type 2 diabetes, and metabolic syndrome. As global obesity rates have climbed, so has the prevalence of fatty liver disease. In the United States alone, an estimated 80 to 100 million people are affected. Despite these staggering numbers, the medical community has largely relied on lifestyle modifications — diet and exercise — as the primary intervention.

That gap between the scale of the problem and the available treatments is precisely what makes the Hebrew University findings so significant.

The Science Behind the Discovery

The Phosphocreatine Connection

One of the study's most striking findings involves phosphocreatine, a molecule that functions as a rapid energy reserve in cells. Think of it as a backup battery for the liver.

When the liver is stressed by a high-fat diet, its energy systems become overwhelmed. The researchers found that both CBD and CBG increase phosphocreatine levels in liver cells, essentially providing the organ with additional energy reserves to cope with metabolic stress.

This phosphocreatine buffering effect helps liver cells maintain normal function even under the strain of excess fat accumulation. It is a fundamentally different approach from most metabolic interventions, which typically focus on reducing fat intake rather than strengthening the liver's ability to handle it.

Restoring the Cellular Cleanup Crew

The second mechanism involves lysosomes, which are essentially the cell's recycling centers. Within these structures, enzymes called cathepsins break down cellular waste, damaged proteins, and accumulated fats.

In fatty liver disease, cathepsin activity becomes impaired. The recycling centers stop functioning efficiently, and harmful materials accumulate. CBD and CBG were shown to restore cathepsin activity, getting the cellular cleanup crew back to work.

By reactivating this system, the liver becomes better equipped to break down and clear out harmful fats and waste products. The researchers describe this as a lysosomal restoration process — not just treating symptoms, but actually repairing the underlying dysfunction.

Metabolic Improvements Across the Board

Beyond these primary mechanisms, the study documented broad metabolic improvements. Both CBD and CBG significantly reduced harmful lipids, including triglycerides and ceramides. Ceramides are particularly noteworthy because they contribute directly to insulin resistance and liver inflammation — two factors that drive fatty liver disease progression.

Blood sugar control improved under both treatments. Insulin sensitivity increased. The overall metabolic profile of treated subjects shifted toward healthier baselines.

CBD vs. CBG: A Tale of Two Cannabinoids

While both compounds showed therapeutic promise, CBG appeared to outperform CBD on several key metrics. CBG demonstrated more pronounced effects on body fat mass reduction and insulin sensitivity improvement. It was also particularly effective at lowering total cholesterol and LDL cholesterol — the so-called bad cholesterol that contributes to cardiovascular disease.

This finding is especially interesting because CBG has historically received far less research attention than CBD. Often called the "mother of all cannabinoids" because other cannabinoids are synthesized from its precursor acid form, CBG is present in most cannabis strains at concentrations below 1 percent. However, breeders have developed high-CBG cultivars in recent years, and the compound has gained traction in the wellness market.

The superior performance of CBG in this study could accelerate both research investment and consumer interest in CBG-specific products.

What This Means for Patients

The study's lead researchers emphasize that these results, while encouraging, were obtained in preclinical models. Translating these findings to human patients will require clinical trials to determine optimal dosing, delivery methods, and long-term safety profiles.

However, the biological mechanisms identified — phosphocreatine buffering and lysosomal restoration — are well understood in human physiology. The pathways that CBD and CBG activate are conserved across species, which provides a reasonable basis for optimism about human applicability.

For the millions of people currently managing fatty liver disease through diet and exercise alone, this research offers hope that targeted cannabinoid therapies could become part of the treatment toolkit within the next decade.

The Broader Implications for Cannabinoid Medicine

This study adds to a growing body of evidence that non-psychoactive cannabinoids have therapeutic potential far beyond the pain and anxiety applications that dominate current consumer markets. CBD and CBG are emerging as compounds with genuine metabolic benefits, supported by rigorous scientific methodology.

The timing is also notable. With marijuana's reclassification to Schedule III under the Controlled Substances Act, researchers now face fewer regulatory barriers to conducting cannabinoid studies. The Hebrew University team's work could inspire similar investigations at American institutions, where Schedule III classification opens doors to federal research funding and streamlined approval processes.

The Road Ahead

The researchers have indicated that human clinical trials are the logical next step. Given the prevalence of fatty liver disease and the absence of approved pharmacological treatments, there is both scientific justification and market incentive to move forward quickly.

In the meantime, it would be premature for individuals to self-treat fatty liver disease with over-the-counter CBD or CBG products. The dosages, formulations, and delivery methods used in the study may differ significantly from consumer products. Anyone concerned about liver health should consult with a healthcare provider.

What this study does provide is something increasingly rare in cannabis science: a clear, mechanistic explanation for how specific cannabinoids affect a specific disease process. That level of scientific rigor is exactly what the field needs to move from anecdotal claims to evidence-based medicine.

Ready to put this into practice? Use Budpedia to find a dispensary near you and compare verified menus across thousands of licensed retailers.